amantadine has been researched along with Dementia in 18 studies
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source
Dementia: An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this study is to compare the occurrence of dementia among Parkinson's disease (PD) patients treated with amantadine (AM group) with those never exposed to it (NoAM group)." | 7.73 | Association between amantadine and the onset of dementia in Parkinson's disease. ( Bonuccelli, U; Ceravolo, R; Inzelberg, R; Klein, C; Logi, C; Miniowich, A; Rabey, JM; Rossi, C; Schechtman, E; Strugatsky, R, 2006) |
| "Thalamic dementia is an uncommon type of stroke that presents with disorientation, behavioral changes, and impairment of executive functions, with relative preservation of motor functions." | 5.62 | Thalamic Dementia in Acute Inpatient Rehabilitation-Role for Amantadine? ( Brentlinger, G; Ghebrendrias, Y; Han, J; Kim, K; Mohan, A; Yeh, BY, 2021) |
| "Nineteen patients with senile brain disease (including 2 with parkinsonian symptoms) were treated with amantadine in an oral dosage of 200--300 mg daily." | 5.26 | Amantadine in senile dementia: electroencephalographic and clinical effects. ( Boillat, J; Cole, M; Dastoor, DP; Klingner, A; Müller, HF, 1979) |
| " Drugs used to treat PD, such as levodopa, offer symptomatic relief but often have neuropsychiatric adverse effects, most prominently psychosis and delirium." | 4.79 | Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment. ( Camicioli, R; Ganzini, L; Young, BK, 1997) |
| "The objective of this study is to compare the occurrence of dementia among Parkinson's disease (PD) patients treated with amantadine (AM group) with those never exposed to it (NoAM group)." | 3.73 | Association between amantadine and the onset of dementia in Parkinson's disease. ( Bonuccelli, U; Ceravolo, R; Inzelberg, R; Klein, C; Logi, C; Miniowich, A; Rabey, JM; Rossi, C; Schechtman, E; Strugatsky, R, 2006) |
| "Memantine was investigated in a phase II double-blind trial on 30 elderly patients by comparison with a placebo with the aid of several psychometric tests." | 2.66 | Treatment of impaired cerebral function in psychogeriatric patients with memantine--results of a phase II double-blind study. ( Ambrozi, L; Danielczyk, W, 1988) |
| "Thalamic dementia is an uncommon type of stroke that presents with disorientation, behavioral changes, and impairment of executive functions, with relative preservation of motor functions." | 1.62 | Thalamic Dementia in Acute Inpatient Rehabilitation-Role for Amantadine? ( Brentlinger, G; Ghebrendrias, Y; Han, J; Kim, K; Mohan, A; Yeh, BY, 2021) |
| "Nineteen patients with senile brain disease (including 2 with parkinsonian symptoms) were treated with amantadine in an oral dosage of 200--300 mg daily." | 1.26 | Amantadine in senile dementia: electroencephalographic and clinical effects. ( Boillat, J; Cole, M; Dastoor, DP; Klingner, A; Müller, HF, 1979) |
| " In the antipsychotic classification, special attention is given to side effects (extrapyramidal motor signs, tardive dyskinesias, akathisis) and to dosage for the elderly." | 1.25 | Observations on the psychopharmacology of the aged. ( Eisdorfer, C, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (55.56) | 18.7374 |
| 1990's | 3 (16.67) | 18.2507 |
| 2000's | 2 (11.11) | 29.6817 |
| 2010's | 1 (5.56) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, K | 1 |
| Mohan, A | 1 |
| Yeh, BY | 1 |
| Ghebrendrias, Y | 1 |
| Brentlinger, G | 1 |
| Han, J | 1 |
| Chang, MC | 1 |
| Wang, F | 1 |
| Feng, TY | 1 |
| Yang, S | 1 |
| Preter, M | 1 |
| Zhou, JN | 1 |
| Wang, XP | 1 |
| Swarztrauber, K | 1 |
| Koudelka, C | 1 |
| Brodsky, MA | 1 |
| Inzelberg, R | 1 |
| Bonuccelli, U | 1 |
| Schechtman, E | 1 |
| Miniowich, A | 1 |
| Strugatsky, R | 1 |
| Ceravolo, R | 1 |
| Logi, C | 1 |
| Rossi, C | 1 |
| Klein, C | 1 |
| Rabey, JM | 1 |
| Allen, RM | 1 |
| Gradner, W | 1 |
| Schnaberth, G | 1 |
| Auff, E | 1 |
| Young, BK | 1 |
| Camicioli, R | 1 |
| Ganzini, L | 1 |
| Eisdorfer, C | 1 |
| Müller, HF | 1 |
| Dastoor, DP | 1 |
| Klingner, A | 1 |
| Cole, M | 1 |
| Boillat, J | 1 |
| Semlitsch, HV | 1 |
| Anderer, P | 1 |
| Saletu, B | 1 |
| Hermesh, H | 1 |
| Sirota, P | 1 |
| Eviatar, J | 1 |
| Sawada, H | 1 |
| Akiguchi, I | 1 |
| Kimura, T | 1 |
| Fukuyama, H | 1 |
| Kameyama, M | 1 |
| Harvey, NS | 1 |
| Otomo, E | 1 |
| Ambrozi, L | 1 |
| Danielczyk, W | 1 |
| Powell, HC | 1 |
| London, GW | 1 |
| Lampert, PW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of a Modified Mindfulness-based Cognitive Therapy for Family Caregivers of People With Dementia in Stress Reduction: A Randomized Controlled Trial[NCT03354819] | 113 participants (Actual) | Interventional | 2017-12-23 | Completed | |||
| Feru-guard (Ferulic Acid and Angelica Archangelica Extract) for Behavioral Symptoms in Dementia[NCT03451760] | Phase 2 | 70 participants (Anticipated) | Interventional | 2018-09-30 | Not yet recruiting | ||
| An Investigation of the Antidepressant Efficacy of Memantine, an NMDA Antagonist With Neurotrophic Properties in Major Depression[NCT00040261] | Phase 3 | 112 participants | Interventional | 2002-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for amantadine and Dementia
| Article | Year |
|---|---|
Drug Therapy for Behavioral and Psychological Symptoms of Dementia.
Topics: Amantadine; Antidepressive Agents; Antipsychotic Agents; Behavioral Symptoms; Cholinesterase Inhibit | 2016 |
Drug Therapy for Behavioral and Psychological Symptoms of Dementia.
Topics: Amantadine; Antidepressive Agents; Antipsychotic Agents; Behavioral Symptoms; Cholinesterase Inhibit | 2016 |
Drug Therapy for Behavioral and Psychological Symptoms of Dementia.
Topics: Amantadine; Antidepressive Agents; Antipsychotic Agents; Behavioral Symptoms; Cholinesterase Inhibit | 2016 |
Drug Therapy for Behavioral and Psychological Symptoms of Dementia.
Topics: Amantadine; Antidepressive Agents; Antipsychotic Agents; Behavioral Symptoms; Cholinesterase Inhibit | 2016 |
Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment.
Topics: Aging; Akathisia, Drug-Induced; Amantadine; Antiparkinson Agents; Antipsychotic Agents; Cholinergic | 1997 |
Psychiatric disorders in parkinsonism: 2. Organic cerebral states and drug reactions.
Topics: Amantadine; Antiparkinson Agents; Atrophy; Brain; Bromocriptine; Cognition; Dementia; Dreams; Drug I | 1986 |
2 trials available for amantadine and Dementia
| Article | Year |
|---|---|
Topographic mapping of long latency "cognitive" event-related potentials (P 300): a double-blind, placebo-controlled study with amantadine in mild dementia.
Topics: Aged; Amantadine; Brain; Brain Mapping; Cognition; Dementia; Double-Blind Method; Electrooculography | 1992 |
Treatment of impaired cerebral function in psychogeriatric patients with memantine--results of a phase II double-blind study.
Topics: Aged; Amantadine; Dementia; Double-Blind Method; Drug Evaluation; Female; Humans; Male; Memantine; N | 1988 |
13 other studies available for amantadine and Dementia
| Article | Year |
|---|---|
Thalamic Dementia in Acute Inpatient Rehabilitation-Role for Amantadine?
Topics: Amantadine; Cerebral Infarction; Dementia; Dopamine Agents; Humans; Male; Middle Aged; Thalamic Nucl | 2021 |
Comments on "Thalamic Dementia in Acute Inpatient Rehabilitation-Role for Amantadine? A Case Report".
Topics: Amantadine; Dementia; Humans; Inpatients; Thalamus | 2021 |
Initial pharmacotherapy in a population of veterans with Parkinson disease.
Topics: Age Factors; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Cholinergic Antagonists; Dat | 2006 |
Association between amantadine and the onset of dementia in Parkinson's disease.
Topics: Aged; Amantadine; Antiparkinson Agents; Comorbidity; Dementia; Female; Humans; Male; Mental Status S | 2006 |
Palliative treatment of tardive dyskinesia with combination of amantadine-neuroleptic administration.
Topics: Adult; Aged; Amantadine; Antipsychotic Agents; Dementia; Dose-Response Relationship, Drug; Drug Ther | 1982 |
[The Steel Richardson Olszewski-syndrome. A report on 3 further cases (author's transl)].
Topics: Amantadine; Biperiden; Bulbar Palsy, Progressive; Dementia; Dysarthria; Humans; Male; Middle Aged; O | 1981 |
[Dementia--Parkinson disease: role of antiglutamatergic drugs. Symposium: 4 April, Hamburg].
Topics: Amantadine; Antipsychotic Agents; Dementia; Humans; Levodopa; Movement Disorders; Parkinson Disease; | 1998 |
Observations on the psychopharmacology of the aged.
Topics: Aged; Amantadine; Antidepressive Agents; Antipsychotic Agents; Basal Ganglia Diseases; Butyrophenone | 1975 |
Amantadine in senile dementia: electroencephalographic and clinical effects.
Topics: Administration, Oral; Aged; Amantadine; Anxiety; Dementia; Depression; Electroencephalography; Femal | 1979 |
Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine.
Topics: Aged; Amantadine; Dementia; Drug Therapy, Combination; Haloperidol; Humans; Male; Neuroleptic Malign | 1989 |
[A case of venous dural sinus thrombosis presenting dementia syndrome. An autopsy case].
Topics: Amantadine; Brain; Calcinosis; Dementia; Humans; Male; Middle Aged; Sinus Thrombosis, Intracranial | 1989 |
[Drug therapy of Alzheimer's disease. General concepts on nootropic drugs].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amantadine; Aminoacridines; Dementia; gamma-Aminobutyric | 1988 |
Neurofibrillary tangles in progressive supranuclear palsy. Electron microscopic observations.
Topics: Aged; Amantadine; Brain; Brain Diseases; Bulbar Palsy, Progressive; Dementia; Dihydroxyphenylalanine | 1974 |